Management of Fetal Demise caused by Abruption at Term
2/1/2016 - Shari M. Lawson, MD
Mentor: Nancy D. Gaba, MD
Editor: Daniel Breitkopf, MD
Placental abruption complicates 0.5 to 1% of pregnancies, but very rarely results in fetal demise. Fetuses that survive are at increased risk of significant morbidity. Management must address maternal and fetal status, severity of the abruption, and gestational age and viability of the fetus. When placental abruption results in fetal demise, there should be significant concern that the abruption is severe and potentially life threatening to the mother as well.
The initial evaluation needs to include a comprehensive history and physical exam to identify causes of abruption that could impact management such as hypertensive disorders of pregnancy, abdominal trauma, or cocaine use. The mother’s hemodynamic status must be closely evaluated and monitored. Fetal demise should raise concern for significant hemorrhage. Two large-bore intravenous catheters should be placed and volume resuscitation initiated with crystalloid or uncross-matched O negative blood as clinically warranted. Blood samples should be sent for type and crossmatch, complete blood count, fibrinogen, and PT/aPTT to assess for acute blood loss anemia and coagulopathy. Elevated d-dimer may be associated with severe placental abruption, but is not diagnostic. Consumptive coagulopathy (disseminated intravascular coagulation) is more common with concealed abruption.
The patient should also be assessed for vaginal bleeding and for concealed retroplacental hemorrhage. Bleeding per vagina can be assessed objectively with either a volumetric container or by weighing items used to absorb blood such as underpads and linen. Concealed hemorrhage may be assessed serially by ultrasonography or measuring fundal height. Ultrasonography may miss some cases of placental abruption, as the echotexture of clot is similar to that of placenta. Ultrasonography should be performed to determine fetal presentation and confirm fetal demise.
Many patients who have experienced a severe abruption and fetal demise have regular contractions on tocodynamometer and may deliver spontaneously. Vaginal delivery is the preferred route as the coagulopathy associated with abruption may complicate cesarean delivery. Prior classical cesarean is not an absolute contraindication for vaginal delivery, but the decision and counseling should weigh the risks of surgical hemorrhage due to coagulopathy against the risks of uterine rupture (4-9% with prior classical cesarean). Amniotomy or oxytocin augmentation will usually result in a rapid vaginal delivery. During labor, ongoing blood loss should be noted and replaced as necessary.
In the presence of placental abruption, cesarean delivery has a significant risk of intraoperative hemorrhage due to atony or coagulopathy potentially leading to peripartum hysterectomy. If surgical delivery is necessary, marked thrombocytopenia (platelets less than 50,000/µL) or hypofibrinogenemia (fibrinogen less than 100 mg/dL) should be corrected with platelet or cryoprecipitate infusion to mitigate the risk of intraoperative hemorrhage. Packed red blood cells should be transfused to maintain the hematocrit between 25 and 30%. Massive transfusion protocols should be initiated if necessary.
Couvelaire uterus, defined as widespread extravasation of blood into the myometrium and beneath the serosa, may be encountered but is not necessarily an indication for hysterectomy. Rh immunoglobulin should be administered per protocol.
American College of Obstetricians and Gynecologists, ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol. 2009 Mar;113(3):748-61. doi: 10.1097/AOG.0b013e31819e9ee2.
Initial approval November 2015; Reaffirmed May 2017; Revised November 2018.
********** Notice Regarding Use ************
The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2018 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.
Back to Search Results